Prosecution Insights
Last updated: April 19, 2026

Examiner: SPENCER, ANDREA LYNNE MORRIS

Tech Center 1600 • Art Units: 1631

This examiner grants 33% of resolved cases

Performance Statistics

33.3%
Allow Rate
-26.7% vs TC avg
48
Total Applications
-33.3%
Interview Lift
1175
Avg Prosecution Days
Based on 3 resolved cases, 2023–2026

Rejection Statute Breakdown

3.3%
§101 Eligibility
21.8%
§102 Novelty
38.4%
§103 Obviousness
26.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18194691 ANKYRIN-RICH BTB/POZ DOMAIN-CONTAINING PROTEIN-2 (ABTB2) FOR SUPPRESSING PANCREATIC CANCER GROWTH Non-Final OA The Curators of the University of Missouri
18094851 SYSTEMS AND METHODS TO MODEL ADAPTIVE IMMUNE RESPONSES Non-Final OA The Board of Trustees of the Leland Stanford Junior University
17716269 CELL CULTURE FOR TREATING INFLAMMATORY DISEASE Final Rejection TERUMO KABUSHIKI KAISHA
17912747 METHOD FOR INDUCING DIFFERENTIATION INTO PANCREATIC ALPHA CELLS Final Rejection NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
17996569 GENETICALLY MANIPULATED CELL STRAIN FOR ACTIVATING AND AMPLIFYING NK CELLS AND USE THEREOF Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18031470 POLOXAMERS FOR CELL CULTURE Non-Final OA MERCK PATENT GMBH
17997110 COMPOSITIONS AND METHODS FOR REDUCING NUCLEASE EXPRESSION AND OFF-TARGET ACTIVITY USING A PROMOTER WITH LOW TRANSCRIPTIONAL ACTIVITY Non-Final OA The Trustees of the University of Pennsylvania
17639962 ADENO-ASSOCIATED VIRUS VECTOR PLATFORM FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF Non-Final OA University of Massachusetts
18012024 METHODS OF GENERATING HEMATOPOIETIC CELL PREPARATIONS Non-Final OA The Penn State Research Foundation
17407606 NONVIRAL GENERATION OF GENOME EDITED CHIMERIC ANTIGEN RECEPTOR T CELLS Non-Final OA Wisconsin Alumni Research Foundation
17628913 Targeted RNA cleavage with CRISPR-Cas Final Rejection University of Rochester
18391547 HIGH PRODUCTION OF RECOMBINANT PROTEIN BY MAKING CELL HYBRIDS AND ENRICHING FOR A PREFERRED MITOCHONDRIAL PHENOTYPE Final Rejection CHO Plus, Inc.
18288146 UV A LIGHT EXPOSURE INCREASES MITOCHONDRIAL ANTI-VIRAL PROTEIN EXPRESSION IN TRACHEAL CELLS VIA CELL-TO-CELL COMMUNICATION AND USES THEREOF Non-Final OA Cedars-Sinai Medical Center
17954138 Methods for the Storage of Whole Blood, and Compositions Thereof Non-Final OA Hemanext Inc.
18038976 MOLONEY MURINE LEUKEMIA VIRUS-BASED SELF-INACTIVATING VECTOR AND APPLICATIONS THEREOF Non-Final OA YUNZHOU BIOSCIENCES (GUANGZHOU) CO., INC.
17896781 Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons Non-Final OA Trailhead Biosystems Inc.
17793360 CELL EXPANSION METHODS FOR PREVENTING CELL SENESCENCE AND PRESERVING THE THERAPEUTIC POTENCY OF HUMAN MESENCHYMAL STEM CELLS Final Rejection Timothy LOGAN
17787948 ADIPOSE TISSUE CRYOPRESERVATION PROTECTIVE AGENT Non-Final OA SHANGHAI ZHONGSHENG AURORA BIOTECHNOLOGY CO., LTD.
17610925 METHOD FOR ADMINISTERING ONCOLYTIC VIRUS TO TUMOR TISSUE, AND DEVICE FOR ADMINISTRATION Final Rejection ONCOLYS BIOPHARMA INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month